Microplate Dx

Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.

Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobial resistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale.

Microplate Dx headquartered in Europe, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $37.5M in funding across 12 round(s). With a team of 11-50 employees, Microplate Dx is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Microplate Dx, raised $3.1M. Discover more about their projects, partnerships, and impact on our platform.